Dr. Tu assists clients in all aspects of patent related matters, including drafting and prosecution of patent applications, re-examination and invalidation procedures, validity/patentability analysis, freedom-to-operate opinions, landscape analysis and due diligence, with a profession in the fields of life science, especially biotechnology, biopharmaceutical and immunotherapy.

Dr. Tu started his IP career with Liu, Shen & Associates in 2015. Prior to joining Liu, Shen & Associates, Dr. Tu obtained his Ph.D. of Cell Biology from University of Chinese Academy of Sciences in 2015, and B.S. of Biology from Wuhan University in 2009.  During His Ph.D. research, Dr. Tu focused on identification of target molecules and development of therapeutic antibodies for cancer treatment.

From 2015 to 2021, Dr. Tu majors in drafting, prosecution and reexamination of patent applications in a variety of technical fields of biopharmaceutical and biotechnology, including immunotherapy, antibody/ADC drugs, vaccines, gene therapy, gene editing, stem cell, enzymatic science, transgenic animals and microbiology, before multiple patent offices (CN, US, EP, JP, KR and others). He has gained in-depth understanding in Chinese IP laws and patent practice, as well as laws and practice under other major jurisdictions.

From 2018 to 2021, Dr. Tu has done significant work in patent invalidation and pre-litigation analysis, validity/patentability analysis, freedom-to-operate opinion, landscape analysis, trade secret and due diligence for foreign and local enterprises, including a number of programs relating to antibody/ADC drugs, immunotherapies and gene therapies.

Representative cases that Dr. Tu has participated include

-      Assisting a pharmaceutical company in Beijing in a license-in agreement of two bi-specific antibody related projects from an international enterprise (2019);

-      Assisting a pharmaceutical company in Shanghai in its IPO, providing IP related due diligence on its product pipelines (2020);

-      Assisting a pharmaceutical company in Beijing in a license-in agreement of an antibody-drug conjugated (ADC) related project from an international enterprise (2020);

-      Assisting an investment corporation in investing multiple ADC related projects of several pharmaceutical companies in Beijing and Zhejiang (2020-2021);

-      Providing freedom-to-operate opinions for an international pharmaceutical company regarding its two therapeutic polypeptide related products (2020);

-      Assisting an investment corporation in investing a microbial fermentation related project of a company in Beijing (2020-2021);

-      Assisting an investment corporation in investing a T cell therapy related project of a company in Beijing (2021);

-      Assisting a pharmaceutical company in Beijing in its IPO, providing IP related due diligence on the product pipelines (2021);

-      Assisting an investment corporation in investing an oncolytic virus related project of a pharmaceutical company in Zhejiang (2021);

-      Providing freedom-to-operate opinions for an oncolytic virus related project for a pharmaceutical company in Guangdong (2021);

-      Assisting an investment corporation in investing several cell-based therapy projects of a pharmaceutical company in Guangdong (2021);

-      Providing landscape analysis regarding a therapeutic peptide product for an international enterprise (2021).